At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Efficacy, Safety and Tolerability of RO5186582 in Adults and Adolescents with Down Syndrome
The purpose of this study is to evaluate the effectiveness of 26 weeks of treatment with RO5186582 on working memory and the level of independent functioning/adaptive behavior or global improvement as compared to placebo. About 180 people who have Down syndrome are expected to take part in this study. The study will be conducted in approximately 10 to 15 countries and will last for about 10 months. Up to 25 subjects are expected to enroll at the Rush University Medical Center site.
The Sections of Developmental-Behavioral Pediatrics and Pediatric Neurology are participating in a study of the investigational drug RO5186582 for the treatment of adults and adolescents with Down syndrome. The goal of this study is to evaluate the effects of RO5186582 on working memory, independent functioning, adaptive behavior and global improvement.
In order to participate you must meet the following criteria:
- Have a clinical diagnosis of Down syndrome.
- Are between 12 and 30 years of age.
This is a partial list of eligibility requirements.